Department of Genetics, Institute of Biosciences, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil.
Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Metab Brain Dis. 2022 Aug;37(6):2089-2102. doi: 10.1007/s11011-021-00872-8. Epub 2021 Nov 19.
Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by pathogenic variants in the iduronate-2-sulfatase gene (IDS), responsible for the degradation of glycosaminoglycans (GAGs) heparan and dermatan sulfate. IDS enzyme deficiency results in the accumulation of GAGs within cells and tissues, including the central nervous system (CNS). The progressive neurological outcome in a representative number of MPSII patients (neuronopathic form) involves cognitive impairment, behavioral difficulties, and regression in developmental milestones. In an attempt to dissect part of the influence of axon guidance instability over the cognitive impairment presentation in MPS II, we used brain expression data, network propagation, and clustering algorithm to prioritize in the human interactome a disease module associated with the MPS II context. We identified new candidate genes and pathways that act in focal adhesion, integrin cell surface, laminin interactions, ECM proteoglycans, cytoskeleton, and phagosome that converge into functional mechanisms involved in early neural circuit formation defects and could indicate clues about cognitive impairment in patients with MPSII. Such molecular changes during neurodevelopment may precede the morphological and clinical evidence, emphasizing the importance of an early diagnosis and directing the development of potential drug leads. Furthermore, our data also support previous hypotheses pointing to shared pathogenic mechanisms in some neurodegenerative diseases.
黏多糖贮积症 II 型(MPS II)是一种溶酶体贮积病,由艾杜糖-2-硫酸酯酶基因(IDS)的致病性变异引起,该基因负责降解糖胺聚糖(GAGs)肝素和硫酸皮肤素。IDS 酶缺乏导致 GAG 在细胞和组织内积累,包括中枢神经系统(CNS)。在相当数量的 MPSII 患者(神经病变形式)中,进行性神经学结局涉及认知障碍、行为困难和发育里程碑的倒退。为了剖析轴突导向不稳定对 MPS II 认知障碍表现的部分影响,我们使用大脑表达数据、网络传播和聚类算法,在人类相互作用组中优先确定与 MPS II 背景相关的疾病模块。我们确定了新的候选基因和途径,这些基因和途径在焦点黏附、整合素细胞表面、层粘连蛋白相互作用、细胞外基质蛋白聚糖、细胞骨架和吞噬体中发挥作用,这些途径汇聚到涉及早期神经回路形成缺陷的功能机制中,并可能提示 MPS II 患者认知障碍的线索。这些神经发育过程中的分子变化可能先于形态和临床证据,强调早期诊断的重要性,并指导潜在药物先导物的开发。此外,我们的数据还支持了先前的假设,即一些神经退行性疾病存在共同的致病机制。